A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Primary Biliary Cholangitis
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2018
At a glance
- Drugs Tropifexor (Primary)
- Indications Biliary cirrhosis; Cholangitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 18 Apr 2018 Planned number of patients changed from 152 to 163.
- 18 Apr 2018 Planned End Date changed from 5 May 2019 to 10 Dec 2019.
- 18 Apr 2018 Planned primary completion date changed from 27 Dec 2017 to 10 Dec 2019.